TG Therapeutics Inc [NASDAQ: TGTX] slipped around -0.17 points on Thursday, while shares priced at $37.06 at the close of the session, down -0.46%.
Compared to the average trading volume of 2.51M shares, TGTX reached a trading volume of 4299895 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about TG Therapeutics Inc [TGTX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TGTX shares is $42.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TGTX stock is a recommendation set at 1.38. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
TD Cowen have made an estimate for TG Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 29, 2024. While these analysts kept the previous recommendation, Goldman dropped their target price from $16 to $12. The new note on the price target was released on August 02, 2023, representing the official price target for TG Therapeutics Inc stock. Previously, the target price had yet another drop from $55 to $40, while Jefferies kept a Buy rating on TGTX stock.
The Average True Range (ATR) for TG Therapeutics Inc is set at 2.13, with the Price to Sales ratio for TGTX stock in the period of the last 12 months amounting to 17.69. The Price to Book ratio for the last quarter was 25.97, with the Price to Cash per share for the same quarter was set at 1.98.
How has TGTX stock performed recently?
TG Therapeutics Inc [TGTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.31. With this latest performance, TGTX shares gained by 19.13% in over the last four-week period, additionally plugging by 57.50% over the last 6 months – not to mention a rise of 126.39% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TGTX stock in for the last two-week period is set at 63.83, with the RSI for the last a single of trading hit 65.08, and the three-weeks RSI is set at 61.83 for TG Therapeutics Inc [TGTX]. The present Moving Average for the last 50 days of trading for this stock 31.71, while it was recorded at 37.90 for the last single week of trading, and 25.82 for the last 200 days.
TG Therapeutics Inc [TGTX]: Deeper insight into the fundamentals
TG Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.03 and a Current Ratio set at 6.25.
Earnings analysis for TG Therapeutics Inc [TGTX]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TGTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for TG Therapeutics Inc go to 154.68%.
Insider trade positions for TG Therapeutics Inc [TGTX]
There are presently around $62.89%, or 69.43%% of TGTX stock, in the hands of institutional investors. The top three institutional holders of TGTX stocks are: VANGUARD GROUP INC with ownership of 13.69 million shares, which is approximately 9.3645%. BLACKROCK INC., holding 11.39 million shares of the stock with an approximate value of $$202.6 million in TGTX stocks shares; and BLACKROCK INC., currently with $$119.12 million in TGTX stock with ownership which is approximately 4.5798%.
